Overview

• Lilly posted $15.56 billion in Q2 revenue and $6.31 adjusted EPS, topping analyst estimates on robust sales of Mounjaro and Zepbound.
• Combined tirzepatide revenue climbed to $8.57 billion, with Mounjaro contributing $5.2 billion and Zepbound $3.4 billion, nearly doubling year-over-year sales.
• The company lifted its 2025 guidance to $60 billion–$62 billion in sales and $21.75–$23 in adjusted EPS, up from prior ranges of $58 billion–$61 billion and $20.78–$22.28.
• Late-stage trial data for its oral obesity pill orforglipron showed 12% weight loss at the highest dose, missing expectations and triggering a 12% share drop.
• Lilly noted its outlook excludes President Trump’s proposed drug tariffs and flagged intensifying competition from Novo Nordisk as pricing policies evolve.